about
Mpl traffics to the cell surface through conventional and unconventional routesThe tyrphostin agent AG490 prevents and reverses type 1 diabetes in NOD miceThe natural chemopreventive agent sulforaphane inhibits STAT5 activityResearch and progress on ClC‑2 (Review).Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia.Targeting the JAK-STAT pathway in lymphoma: a focus on pacritinib.Janus kinase 2 polymorphisms are associated with risk in patients with gastric cancer in a Chinese population.The synthetic α-bromo-2',3,4,4'-tetramethoxychalcone (α-Br-TMC) inhibits the JAK/STAT signaling pathway.The Jak2 inhibitor, G6, alleviates Jak2-V617F-mediated myeloproliferative neoplasia by providing significant therapeutic efficacy to the bone marrowThe pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling.Influence of Tyrphostin AG490 on the expression of diabetes-associated markers in human adipocytes.The Chemopreventive Phytochemical Moringin Isolated from Moringa oleifera Seeds Inhibits JAK/STAT Signaling.Macrophages support pathological erythropoiesis in polycythemia vera and β-thalassemiaMyelofibrosis: an update on current pharmacotherapy and future directions.Therapeutic targeting of IL-7Rα signaling pathways in ALL treatment.Upregulation of the large conductance voltage- and Ca2+-activated K+ channels by Janus kinase 2.MiR-135a targets JAK2 and inhibits gastric cancer cell proliferation.Systematic Analysis of Endometrial Cancer-Associated Hub Proteins Based on Text MiningInhibition of Janus kinases by tyrosine phosphorylation inhibitor, Tyrphostin AG-490.How Does the L884P Mutation Confer Resistance to Type-II Inhibitors of JAK2 Kinase: A Comprehensive Molecular Modeling Study.Prognostication in primary myelofibrosis.Downregulation of KCNQ4 by Janus kinase 2.Up-regulation of Kv1.3 channels by janus kinase 2.Down-regulation of the epithelial Na⁺ channel ENaC by Janus kinase 2.Down-regulation of the myoinositol transporter SMIT by JAK2.Downregulation of the creatine transporter SLC6A8 by JAK2.JAK-2 as a novel mediator of the profibrotic effects of transforming growth factor β in systemic sclerosis.Occurrence of BCR-ABL1-positive chronic myeloid leukemia following essential thrombocythemia.
P2860
Q24299221-883AB908-9B0F-4F2E-B1A5-7FA3A6C1EB40Q28483660-085C0E34-F6BD-4065-A30B-17F4D25C4C09Q28539573-8C802992-38B5-4C6E-8378-4B5DEFE8998FQ33828111-E193441C-24C0-43C3-A4C7-9468F9034F0AQ34640779-F9A32D72-EE74-4BD6-BD45-631E46F8ECBFQ34648812-5AED4884-E590-45CD-BCB8-CCD124AA420FQ34746150-2ED4C844-51F0-422A-A929-1AAE2E8F624AQ35111380-93ED46E7-96B7-4E25-B90F-10E17D71470AQ35571892-586D87DA-3108-4DC1-B5AC-E2AF1F329D0DQ35857092-595CF997-3988-469E-B60B-82381B1FC2F1Q35962215-6C83FE21-688D-40B7-876E-94D0C591045EQ36053065-CF67FA3F-CA52-41F6-923D-DC2A5D33E117Q36745518-952BB62D-6E29-4408-B444-F930B8786B91Q38091447-BE36D8E2-7222-48A1-AD8B-B09A93AE829EQ38856941-CA46AB5D-B683-4670-9651-DFAA441DCFEFQ39008720-F6055BFA-4E94-4E46-9DB9-FEE04A021C6FQ39400620-49CBBAB1-8DF4-4827-A8B6-06266C4037D4Q40543038-1221BE57-5CE7-4A2E-930E-5966C3A7E386Q40897166-10AEA314-35FD-46DD-B668-A5E699B4F104Q41490661-0F5E3745-218E-4A2B-BFF5-52D107773A81Q44731549-27CEED00-5BDD-4D0C-B4CF-DE8BF3F967DCQ45817343-6E051C55-CEA0-401C-8B90-0D9A37EC2AEFQ48586068-C74BA567-68EA-4A4D-BFFE-BC07BE8355A6Q48607961-9F9391F4-C7A1-4CD8-948B-DA526F9D19EFQ48635036-5EED456F-359E-4FEB-A0B8-B5C9E1FF45B0Q48653545-70861D5A-F8D4-4B1F-ADBB-64E540C76272Q54513818-585CE3FB-B44C-4DEA-991F-F0E68C34587DQ54558402-D3034C13-3726-40F3-A590-95F712ABBFA6
P2860
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
JAK2 inhibitors: what's the true therapeutic potential?
@en
JAK2 inhibitors: what's the true therapeutic potential?
@nl
type
label
JAK2 inhibitors: what's the true therapeutic potential?
@en
JAK2 inhibitors: what's the true therapeutic potential?
@nl
prefLabel
JAK2 inhibitors: what's the true therapeutic potential?
@en
JAK2 inhibitors: what's the true therapeutic potential?
@nl
P2860
P1433
P1476
JAK2 inhibitors: what's the true therapeutic potential?
@en
P2093
Fabio P S Santos
P2860
P356
10.1016/J.BLRE.2010.10.004
P577
2010-11-20T00:00:00Z